Compositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
Inventors
Yoon, Seong Jun • Son, Jee Soo • KIM, In Hwang • Paik, Hyoung Rok • OH, Eun Kyoung • Lee, Geun Woo • JUN, Soo Youn • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12280081-B2
Publication Date
2025-04-22
Expiration Date
Abstract
A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
Core Innovation
The invention relates to a method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis by administering to a subject a composition containing Siphoviridae bacteriophage Bac-FRP-5 and a pharmaceutically acceptable carrier. The bacteriophage is deposited in the Korean Collection for Type Culture (KCTC) under accession number KCTC 14403BP and is described with genome information set forth in SEQ ID NO: 1.
Bac-FRP-5 is characterized by lytic ability against enterotoxigenic Bacteroides fragilis cells and by defined genome sequence and structural/functional properties. The bacteriophage has a latent period of 10–100 minutes and a burst size of 150–540 plaque-forming units (PFU)/infected cell, and it has structural proteins in the size range of approximately 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa.
The method is directed to infection or disease caused by enterotoxigenic Bacteroides fragilis and is applicable to conditions including acute or chronic intestinal infection or disease selected from diarrhea, colitis, colonic neoplasia, bacteremia, or colorectal cancer. The composition includes a pharmaceutically acceptable carrier and may further include one or more selected additives.
Claims Coverage
The partial content identifies one independent claim covering a prevention/treatment method for an infection or disease caused by enterotoxigenic Bacteroides fragilis. The claim includes five inventive features: defined phage identity, lytic ability, latent period and burst size, structural protein sizes, and phage concentration range in the administered composition.
Bac-FRP-5 deposited phage with genome sequence
A method comprising administering to a subject a composition containing Siphoviridae bacteriophage Bac-FRP-5 deposited in the Korean Collection for Type Culture (KCTC) under accession number KCTC 14403BP and having a genome sequence as set forth in SEQ ID NO: 1.
Lytic ability against enterotoxigenic Bacteroides fragilis
A method wherein Bac-FRP-5 has an ability to lyse enterotoxigenic Bacteroides fragilis cells.
Defined latent period and burst size
A method wherein Bac-FRP-5 has a latent period of 10–100 minutes and a burst size of 150–540 plaque-forming units (PFU)/infected cell.
Defined structural protein size set
A method wherein Bac-FRP-5 has structural proteins in the size of approximately 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa.
Administered phage concentration range in composition
A method wherein the composition has a concentration of Bac-FRP-5 of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g, together with a pharmaceutically acceptable carrier.
The claim coverage centers on administering a pharmaceutically acceptable composition containing Bac-FRP-5 (KCTC 14403BP, SEQ ID NO: 1) that lyses enterotoxigenic Bacteroides fragilis, with defined latent period, burst size, structural protein sizes, and defined phage concentration ranges.
Stated Advantages
Provides a method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis.
Documented Applications
Prevention or treatment of an infection or disease caused by enterotoxigenic Bacteroides fragilis, including acute or chronic intestinal infection or disease such as diarrhea and colitis.
Prevention or treatment of infection or disease caused by enterotoxigenic Bacteroides fragilis including colonic neoplasia, bacteremia, and colorectal cancer.
Interested in licensing this patent?